Biogen

Biogen

  • July 2020 •
  • 41 pages •
  • Report ID: 5779860 •
  • Format: PDF
PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Biogen’s prescription pharmaceutical business will see stable performance over the medium term.
Key themes – [1] Biogen’s flagship MS portfolio – Tecfidera, Avonex, Plegridy, and Tysabri – remains incredibly stable [2] Spinraza revenues will plateau during the forecast period due to competition from newer products [3] Biogen’s revival of aducanumab is a surprise and will add significant revenue during the forecast period.

Model updates (22 July 2020)

Tecfidera forecast adjusted significantly lower due to litigation outcome resulting in earlier generic competition
Vumerity forecast adjusted lower due to later expected launch in EU and RoW
Imraldi forecast adjusted lower in EU.

Model updates (22 April 2020)

Vumerity forecast adjusted lower due to continued slow launch.

Model updates (30 January 2020)

Spinraza forecast adjusted higher due to continued international growth
Avonex forecast adjusted lower due to continued competition in multiple sclerosis
Vumerity forecast adjusted lower due to initial launch trends.

Model updates (28 October 2019)

Spinraza forecast adjusted lower in the US
Imraldi forecast adjusted higher due to quicker adoption
Ocrevus royalty forecast adjusted higher due to continued ramp of Ocrevus in all types of MS
Aducanumab forecast added.

Model updates (23 July 2019)

Tecfidera sales adjusted lower in 2028 due to patent expiration
Tysabri sales adjusted higher due to less impact from competition
Spinraza sales adjusted lower due to pending competition from Zolgensma and risdiplam
Benepali sales adjusted lower due to stabilization in five major EU markets and RoW
Rituxan/Gazyva royalties adjusted higher due to lower than expected biosimilar impact
Ocrevus royalties adjusted higher due to strong momentum in the US and other global approvals
Vumerity launch delayed to 2020 in the US
Aducanumab removed from forecast after failing Phase III ENGAGE and EMERGE trials
BIIB067 forecast added.